HC Wainwright reiterated their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) in a research note issued to investors on Thursday, MarketBeat.com reports. They currently have a $40.00 price target on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2025 earnings at ($1.12) EPS, Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.19) EPS and Q4 2025 earnings at ($1.21) EPS.
A number of other research firms also recently weighed in on OKUR. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Oppenheimer started coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an “outperform” rating and a $35.00 price objective on the stock.
View Our Latest Analysis on OnKure Therapeutics
OnKure Therapeutics Stock Performance
About OnKure Therapeutics
Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.
Further Reading
- Five stocks we like better than OnKure Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- AI Boom Fuels Demand for Dominion Energy Stock
- Quiet Period Expirations Explained
- Cathie Wood Cuts Robinhood Holdings—Follow Her Lead or Stay Put?
- Manufacturing Stocks Investing
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.